BusinessZynerba Pharmaceuticals Announces Oral Presentation of ZYN002 Data at the 16th NFXF International Fragile X Conference in July 2018By Nasdaq OMXApr 23, 2018, 11:00 AM UTC
BusinessZynerba Pharmaceuticals Provides 2018 Clinical and Corporate UpdateBy Nasdaq OMXJan 3, 2018, 9:30 PM UTC
BusinessZynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X SyndromeBy Nasdaq OMXSep 28, 2017, 10:30 AM UTC
